论文部分内容阅读
目的:探究人工肝支持系统治疗药物性肝病的临床疗效及安全性。方法:选取我院2015年1月~2016年9月收治的药物性肝病的患者100例,将这100例患者随机分为对照组和观察组,两组给予不同的治疗手段。对比两组患者治疗前后的血清指标,以及并发症的发生情况。结果对比两组患者在治疗前后的血清指标,观察组的血清指标明显的发生了改变(P<0.05)。对照组治疗后并发症的发生率为16.00%,观察组治疗后并发症的发生率为4.00%,观察组明显优于对照组,差异具有统计学意义(P<0.05)。结论:对于药物性肝病的患者,在常规的内科治疗方法上给予人工肝支持系统进行治疗,能够明显的提高治疗的疗效以及生存率,帮助患者延长生存的时间,且并发症的发生情况有所降低,安全性得到了保障,值得临床上广泛应用。
Objective: To investigate the clinical efficacy and safety of artificial liver support system in the treatment of drug-induced liver disease. Methods: One hundred patients with drug-induced liver disease admitted from January 2015 to September 2016 in our hospital were selected. The 100 patients were randomly divided into control group and observation group. Two groups were given different treatment methods. The serum indexes before and after treatment were compared between two groups of patients and the incidence of complications. Results The serum indexes of the two groups were compared before and after treatment, and the serum indexes of the observation group obviously changed (P <0.05). The incidence of complications in the control group was 16.00%. The incidence of complications in the observation group was 4.00%. The observation group was significantly better than the control group, the difference was statistically significant (P <0.05). CONCLUSIONS: For patients with drug-induced liver disease, artificial liver support system is used in conventional medical treatment, which can obviously improve the curative effect and survival rate of patients and prolong the survival time of patients, and the complication occurs Reduce, safety has been protected, it is widely used in clinical.